...">
Year-to-date, the stock was up slightly more than 12% while benchmark global indices have all fallen sharply amid surging inflation, interest rate hikes and slowdown worries. And never invest or trade money you cannot afford to lose. If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. A Warner Bros. AbbVie: Modelling The Post Humira Bull Case To 2030 (ABBV) To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. Management has previously stated that it expects total revenues to decline in 2023 following the Humira LOE, followed by a return to growth in 2024, and a "high single digit CAGR" maintained through the remainder of the decade. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. What is ABBV's Earnings Per Share (EPS) forecast for 2023-2025? That is substantially higher than the 12% CAGR achieved between 2018 - 2022, although that period includes the additional revenues from Allergan. The acquisition expanded AbbVies neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? Abbvie Stock Forecast 2023, 2024, 2025, 2030 - Stock in US My No. This suggests a possible upside of 3.2% from the stock's current price. Ltd., AbbVie Overseas S. r.l., AbbVie Oy, AbbVie Participaes Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. The difference between trading assets and CFDs. AbbVie's stock is owned by many different institutional and retail investors. Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. AbbVie sees strong 2022 earnings as Botox, Skyrizi power profit beat